[go: up one dir, main page]

SG10201809701TA - Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent - Google Patents

Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Info

Publication number
SG10201809701TA
SG10201809701TA SG10201809701TA SG10201809701TA SG10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA
Authority
SG
Singapore
Prior art keywords
peptide
chemotherapeutic agent
mutant ras
vaccine
cancer
Prior art date
Application number
SG10201809701TA
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809701T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of SG10201809701TA publication Critical patent/SG10201809701TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PEPTIDE VACCINE COMPRISING MUTANT RAS PEPTIDE AND CHEMOTHERAPEUTIC AGENT There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent. Fig. 2
SG10201809701TA 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent SG10201809701TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06

Publications (1)

Publication Number Publication Date
SG10201809701TA true SG10201809701TA (en) 2018-12-28

Family

ID=50679896

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608712PA SG11201608712PA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
SG10201809701TA SG10201809701TA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608712PA SG11201608712PA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Country Status (16)

Country Link
US (1) US9757439B2 (en)
EP (1) EP3140320B1 (en)
JP (2) JP2017514847A (en)
KR (1) KR20170002563A (en)
CN (1) CN106414493A (en)
AU (1) AU2015257774B2 (en)
BR (1) BR112016025764A2 (en)
CA (1) CA2947963A1 (en)
CL (1) CL2016002794A1 (en)
DK (1) DK3140320T3 (en)
ES (1) ES2716923T3 (en)
IL (1) IL248671B (en)
MX (1) MX2016014414A (en)
RU (1) RU2700929C2 (en)
SG (2) SG11201608712PA (en)
WO (1) WO2015169804A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811172PA (en) 2013-12-09 2019-01-30 Targovax Asa A peptide mixture
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EA201991804A1 (en) 2017-02-01 2020-02-07 МОДЕРНАТиЭкс, ИНК. IMMUNOMODULATING THERAPEUTIC COMPOSITIONS of mRNA ENCODING PEPTIDES WITH ACTIVATING ONCOGENIC MUTATION
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
TW202015719A (en) 2018-06-19 2020-05-01 美商尼恩醫療公司 New antigens and their uses
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN114681600A (en) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 Universal polypeptide vaccine and application thereof in preparation of medicine for treating/preventing pancreatic cancer
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. Neoantigen compositions and uses thereof
CN113416241B (en) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 Universal antigen peptide library and kit for inducing tumor specific immune response
US20250269001A1 (en) * 2020-07-29 2025-08-28 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells
KR20230058389A (en) * 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 A method for stimulating an immune response against mutant RAS using nucleated cells
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024541968A (en) * 2021-10-28 2024-11-13 ジェネンテック， インコーポレイテッド Systems and methods for identifying MHC-associated antigens for therapeutic intervention - Patents.com
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (en) * 1999-04-30 2001-04-02 Targovax As Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
CN102370974B (en) 2002-12-16 2014-09-17 全球免疫股份有限公司 Yeast-based vaccines as immunotherapy
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG10201811172PA (en) 2013-12-09 2019-01-30 Targovax Asa A peptide mixture

Also Published As

Publication number Publication date
RU2700929C2 (en) 2019-09-24
WO2015169804A1 (en) 2015-11-12
IL248671A0 (en) 2017-01-31
RU2016147527A (en) 2018-06-08
AU2015257774B2 (en) 2018-12-20
EP3140320A1 (en) 2017-03-15
CL2016002794A1 (en) 2017-06-09
KR20170002563A (en) 2017-01-06
IL248671B (en) 2021-08-31
DK3140320T3 (en) 2019-04-15
SG11201608712PA (en) 2016-11-29
RU2016147527A3 (en) 2019-01-21
US9757439B2 (en) 2017-09-12
JP2017514847A (en) 2017-06-08
MX2016014414A (en) 2017-02-23
JP7304629B2 (en) 2023-07-07
US20170065694A1 (en) 2017-03-09
CN106414493A (en) 2017-02-15
ES2716923T3 (en) 2019-06-18
CA2947963A1 (en) 2015-11-12
AU2015257774A1 (en) 2016-12-22
EP3140320B1 (en) 2018-12-26
JP2020100650A (en) 2020-07-02
BR112016025764A2 (en) 2018-01-16

Similar Documents

Publication Publication Date Title
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
IL304717A (en) Anti-cmet antibody drug conjugates and methods their use
MX2019012534A (en) COMBINATION OF ELAFIBRANOR OR DERIVATIVES THEREOF WITH AN ANTI-NASH, ANTIFIBROTIC OR ANTICHOLESTIC AGENT.
IL256687B (en) Isolated tau-binding antibody and use thereof in therapy and diagnosis
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
PL3896064T3 (en) 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS COT MODULATORS IN THE TREATMENT OF CROOHN'S DISEASE AND ULTRASPECTRUM COLITIS
MX2021013837A (en) APPROACH OF COMBINATION IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER.
MD4733B1 (en) Anti-TIGIT antibodies
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MY187540A (en) Compounds active towards bromodomains
BR112017011215A2 (en) pro-flavoring distribution particles
MX2017015226A (en) TETRASUSTITUID ALQUENO COMPOUNDS AND ITS USE.
MX2015015518A (en) Methods and compositions for the treatment of cancer.
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
TWD185782S (en) Computer
PH12017501979A1 (en) Pharmaceutical compound
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
TWD174083S (en) The part of electrical connector
GEP20207081B (en) Process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
AR097179A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FLUPIRTINE
PL3630188T3 (en) A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
TWD180853S (en) Slide rail stopper
HK1242199A1 (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors